

Supplementary Materials

Anti-osteoclastogenic and Antibacterial Effects of Chlorinated Polyketides from the Beibu Gulf Coral-derived Fungus *Aspergillus unguis* GXIMD 02505

Yanting Zhang^{1†}, Zhichao Li^{2†}, Bingyao Huang¹, Kai Liu¹, Shuai Peng¹, Xinming Liu¹, Chenghai Gao¹, Yonghong Liu^{1,*}, Yanhui Tan^{2,*}, and Xiaowei Luo^{1,*}

¹ Institute of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China;

² State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, China;

* Correspondence: yonghongliu@scsio.ac.cn (Y.L.); tyh533@126.com (Y.T.); luoxiaowei1991@126.com (X.L.).

† These authors contributed equally to this work.

Contents of Supporting Information

Figure S1. ^1H NMR spectrum of Aspergillusether J (1) (methanol- <i>d</i> ₄ , 500 MHz).....	3
Figure S2. ^{13}C NMR spectrum of Aspergillusether J (1) (methanol- <i>d</i> ₄ , 125 MHz).....	4
Figure S3. DEPT 135 NMR spectrum of Aspergillusether J (1) (methanol- <i>d</i> ₄ , 125 MHz).....	5
Figure S4. HSQC spectrum of Aspergillusether J (1) (methanol- <i>d</i> ₄).....	6
Figure S5. HMBC spectrum of Aspergillusether J (1) (methanol- <i>d</i> ₄).....	7
Figure S6. NOESY spectrum of Aspergillusether J (1) (methanol- <i>d</i> ₄).....	8
Figure S7. HRESIMS spectrum of Aspergillusether J (1).....	9
Figure S8. UV spectrum of Aspergillusether J (1).....	10
Figure S9. IR spectrum of Aspergillusether J (1).....	10
Figure S10. ^1H NMR spectrum of Aspergillusidone H (3) (methanol- <i>d</i> ₄ , 700 MHz).....	11
Figure S11. ^{13}C NMR spectrum of Aspergillusidone H (3) (methanol- <i>d</i> ₄ , 175 MHz).....	12
Figure S12. DEPT 135 NMR spectrum of Aspergillusidone H (3) (methanol- <i>d</i> ₄ , 175 MHz).....	13
Figure S13. HSQC spectrum of Aspergillusidone H (3) (methanol- <i>d</i> ₄).....	14
Figure S14. HMBC spectrum of Aspergillusidone H (3) (methanol- <i>d</i> ₄).....	15
Figure S15. NOESY spectrum of Aspergillusidone H (3) (methanol- <i>d</i> ₄).....	16
Figure S16. HRESIMS spectrum of Aspergillusidone H (3).....	17
Figure S17. UV spectrum of Aspergillusidone H (3).....	18
Figure S18. IR spectrum of Aspergillusidone H (3).....	18
Figure S19. X ray crystal structure of compound 2	19
Table S1. Energies of 8 at MMFF94 force field.....	19
Table S2. Energies of 8 at B3LYP/6–31+g(d) level in methanol.....	20
Figure S20. The optimized conformers and equilibrium populations of 8	23
Physicochemical data of known compounds 2 , 4 – 8	23
Figure S21. Anti-MRSA activity of compounds 1 – 8 by agar diffusion method. (CHL: Chloramphenicol; SM: Streptomycin; AMP: Ampicillin).....	25
Figure S22. Anti- <i>M. variabilis</i> activity of compounds 1 – 8 by agar diffusion method.....	25
Figure S23. Anti- <i>M. jannaschii</i> activity of compounds 1 – 8 by agar diffusion method.....	26
Figure S24. Anti- <i>V. Pelagius</i> activity of compound 4 by agar diffusion method.....	26
Figure S25. Anti-MRSA activity of compounds 1 , 2 , 4 , 6 , 7 and ampicillin.....	26
Figure S26. Anti- <i>M. variabilis</i> activity of compounds 1 , 2 , 4 , 6 ~ 8 and positive control.....	27
Figure S27. Anti- <i>M. jannaschii</i> activity of compounds 1 , 2 , 4 , 6 , 8 and positive control.....	27
Figure S28. Anti- <i>V. Pelagius</i> activity of compounds 4 and nalidixic acid.....	28
The ITS sequence of <i>Aspergillus unguis</i> GXIMD 02505.....	28




Figure S1. ^1H NMR spectrum of Aspergillusether J (**1**) (methanol- d_4 , 500 MHz)




Figure S2. ^{13}C NMR spectrum of Aspergillus ether J (**1**) (methanol- d_4 , 125 MHz)




Figure S3. DEPT 135 NMR spectrum of Aspergillusether J (1) (methanol-*d*₄, 125 MHz)




Figure S4. HSQC spectrum of Aspergillusether J (**1**) (methanol-*d*₄)




Figure S5. HMBC spectrum of Aspergillusether J (**1**) (methanol-*d*₄)




Figure S6. NOESY spectrum of Aspergillusether J (**1**) (methanol-*d*₄).




Figure S7. HRESIMS spectrum of Aspergillusether J (**1**).




Figure S8. UV spectrum of Aspergillusether J (1).




Figure S9. IR spectrum of Aspergillusether J (1)




Figure S10. ^1H NMR spectrum of Aspergillusidone H (**3**) (methanol- d_4 , 700 MHz)




Figure S11. ^{13}C NMR spectrum of Aspergillusidone H (3) (methanol- d_4 , 175 MHz)




Figure S12. DEPT 135 NMR spectrum of Aspergillusidone H (3) (methanol-*d*₄, 175 MHz)




Figure S13. HSQC spectrum of Aspergillusidone H (3) (methanol- d_4)




Figure S14. HMBC spectrum of Aspergillusidone H (3) (methanol- d_4)




Figure S15. NOESY spectrum of Aspergillusidone H (3) (methanol-*d*₄)


Mass Spectrum SmartFormula Report

Analysis Info

Analysis Name	D:\Data\MS\data\202106\chenchunmei_AU10_pos_22_01_11002.d	Acquisition Date	6/24/2021 8:40:37 AM
Method	LC_Direct Infusion_pos_70-500mz.m	Operator	SCSIO
Sample Name	chenchunmei_AU 10_pos	Instrument	maXis
Comment			255552.00029

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	180 °C
Scan Begin	70 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1500 m/z	Set Charging Voltage	0 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	err [mDa]	mSigma	rdb	e⁻ Conf	N-Rule
389.1159	1	C21H22ClO5	100.00	389.1150	2.2	0.6	18.3	10.5	even	ok
411.0967	1	C21H21ClNaO5	100.00	411.0970	-0.7	-0.3	25.2	10.5	even	ok
777.2248	1	C42H43Cl2O10	100.00	777.2228	2.7	2.1	35.4	20.5	even	ok
799.2043	1	C42H42Cl2NaO10	100.00	799.2047	-0.5	-0.4	45.0	20.5	even	ok

chenchunmei_AU 10_pos_22_01_11002.d
Bruker Compass DataAnalysis 4.1

printed: 6/24/2021 8:44:36 AM

by: SCSIO

Page 1 of 1

Figure S16. HRESIMS spectrum of Aspergillusidone H (3)




Figure S17. UV spectrum of Aspergillusidone H (3)




Figure S18. IR spectrum of Aspergillusidone H (3)




Figure S19. X ray crystal structure of compound 2.

Table S1. Energies of **8** at MMFF94 force field.

Configuration	Conformer	Energy (kcal/mol)	Population (%)
<i>R</i> - 8	1	211.00	35.2
<i>R</i> - 8	2	211.55	28.1
<i>R</i> - 8	3	215.72	5.2
<i>R</i> - 8	4	215.73	2.6
<i>R</i> - 8	5	216.19	4.3
<i>R</i> - 8	6	216.30	4.1
<i>R</i> - 8	7	216.54	3.8
<i>R</i> - 8	8	216.74	3.5
<i>R</i> - 8	9	217.09	1.5
<i>R</i> - 8	10	217.86	2.2
<i>R</i> - 8	11	218.42	0.9
<i>R</i> - 8	12	218.83	1.5
<i>R</i> - 8	13	218.94	1.4
<i>R</i> - 8	14	218.96	0.7
<i>R</i> - 8	15	219.38	1.2
<i>R</i> - 8	16	219.44	0.6
<i>R</i> - 8	17	219.56	1.1
<i>S</i> - 8	1	211.00	17.0
<i>S</i> - 8	2	211.55	27.1
<i>S</i> - 8	3	213.72	11.3
<i>S</i> - 8	4	214.33	8.9
<i>S</i> - 8	5	215.16	6.3
<i>S</i> - 8	6	215.73	5.0
<i>S</i> - 8	7	216.19	4.2
<i>S</i> - 8	8	216.30	2
<i>S</i> - 8	9	216.54	3.6


S-8	10	216.74	1.7
S-8	11	217.09	2.9
S-8	12	217.86	2.1
S-8	13	218.42	1.7
S-8	14	218.96	1.4
S-8	15	219.44	1.1
S-8	16	219.56	0.5
S-8	17	219.57	1.1


Table S2. Energies of **8** at B3LYP/6–31+g(d) level in methanol.

Configuration	Conformer	E (Hartree)	E (kcal/mol)	Population (%)
R-8	1	-846.6892129	-531305.947986879	11.34
R-8	2	-846.6893122	-531306.010298622	12.60
R-8	3	-846.6883416	-531305.401237416	4.50
R-8	4	-846.6888889	-531305.744673639	8.05
R-8	5	-846.6877075	-531305.003333325	2.30
R-8	6	-846.6884325	-531305.458278075	4.96
R-8	7	-846.6893129	-531306.010737879	12.61
R-8	8	-846.6877371	-531305.021907621	2.37
R-8	9	-846.6892137	-531305.948488887	11.35
R-8	10	-846.6877379	-531305.022409629	2.38
R-8	11	-846.6877075	-531305.003333325	2.30
R-8	12	-846.6888885	-531305.744422635	8.04
R-8	13	-846.6877078	-531305.003521578	2.30
R-8	14	-846.685133	-531303.38780883	0.15
R-8	15	-846.688809	-531305.69453559	7.39
R-8	16	-846.6884321	-531305.458027071	4.96
R-8	17	-846.6877383	-531305.022660633	2.38
S-8	1	-846.6892128	-531305.947924128	10.38
S-8	2	-846.6893122	-531306.010298622	11.53
S-8	3	-846.6893125	-531306.010486875	11.54
S-8	4	-846.6892129	-531305.947986879	10.38
S-8	5	-846.6888093	-531305.694723843	6.77
S-8	6	-846.6888889	-531305.744673639	7.36
S-8	7	-846.6877076	-531305.003396076	2.10
S-8	8	-846.6884326	-531305.458340826	4.54
S-8	9	-846.6893129	-531306.010737879	11.54
S-8	10	-846.6877371	-531305.021907621	2.17
S-8	11	-846.6892141	-531305.948739891	10.39
S-8	12	-846.6877379	-531305.022409629	2.17
S-8	13	-846.6877074	-531305.003270574	2.10
S-8	14	-846.6851341	-531303.388499091	0.14
S-8	15	-846.6884317	-531305.457776067	4.54


S-8	16	-846.687738	-531305.02247238	2.17
S-8	17	-846.6852468	-531303.459219468	0.15

R-8






Conf.16 (4.96%)




Conf.17 (2.38%)


S-8



Conf.1 (10.38%)




Conf.2 (11.53%)



Conf.3 (11.54%)




Conf.4 (10.38%)




Conf.5 (6.77%)




Conf.6 (7.36%)



Conf.7 (2.10%)



Conf.8 (4.54%)



Conf.9 (11.54%)





Conf.10 (2.17%)



Conf.11 (10.39%)



Conf.12 (2.17%)






Figure S20. The optimized conformers and equilibrium populations of **8**.

Physicochemical data of known compounds **2**, **4–8**.

Aspergillusether J (**1**): white amorphous solid; UV (MeOH) λ_{max} (log ϵ) 285 (2.40), 207 (3.47) nm; IR (film) ν_{max} 3435, 1683, 1575, 1409, 1338, 1213, 1190, 1070 cm^{-1} ; ^1H NMR (500 MHz, methanol- d_4): δ_{H} 6.01 (1H, s, H-1), 5.12 (1H, br s, H-2''), 3.80 (3H, s, 3'-OCH₃), 2.24 (3H, s, 2'-CH₃), 2.20 (3H, 6-CH₃), 1.64 (3H, s, H₃-4''), 1.52 (3H, d, J = 6.5 Hz, H₃-3''); ^{13}C NMR (125 MHz, methanol- d_4) δ_{C} : 154.7 (C, C-2), 153.5 (C, C-3'), 151.3 (C, C-4), 149.2 (C, C-1'), 138.1 (C, C-6'), 137.2 (C, C-5'), 136.1 (C, C-6), 130.6 (C, C-1''), 127.7 (CH, C-2''), 120.4 (C, C-2'), 118.5 (C, C-4'), 116.2 (C, C-5), 110.2 (C, C-3), 109.4 (CH, C-1), 60.8 (CH₃, 3-OMe), 20.4 (CH₃, 6-CH₃), 16.8 (CH₃, C-4''), 13.6 (CH₃, C-3''), 9.9 (CH₃, 2'-CH₃). HR-ESIMS m/z 417.0414 [M + H]⁺ (calcd for C₁₉H₂₀Cl₃O₄, 417.0427), 415.0285 [M - H]⁻ (calcd for C₁₉H₁₈Cl₃O₄, 415.0271).

Aspergillusether F (**2**): white needle crystals; ^1H NMR (500 MHz, methanol- d_4): δ_{H} 6.00 (1H, s, H-1), 5.10 (1H, br s, H-2''), 2.18 (3H, s, 2'-CH₃), 2.17 (3H, s, 6-CH₃), 1.64 (3H, s, H₃-4''), 1.51 (3H, d, J = 6.8 Hz, H₃-3''); ^{13}C NMR (125 MHz, methanol- d_4) δ_{C} : 155.1 (C, C-2), 151.2 (C, C-4), 150.1 (C, C-3'), 148.8 (C, C-1'), 136.1 (C, C-6), 136.0 (C, C-5'), 134.8 (C, C-6'), 130.8 (C, C-1''), 127.4 (CH, C-2''), 115.9 (C, C-5), 113.7 (C, C-2'), 111.7 (C, C-4'), 110.0 (CH, C-1), 109.4 (C, C-3), 20.4 (CH₃, 6-CH₃), 16.8 (CH₃, C-4''), 13.6 (CH₃, C-3''), 9.7 (CH₃, 2'-CH₃). HR-ESIMS m/z 403.0255 [M + H]⁺ (calcd for C₁₈H₁₈Cl₃O₄, 403.0271).

Nornidulin (**4**): colorless solid; ^1H NMR (500 MHz, methanol- d_4): δ_{H} 5.38 (1H, q, J = 6.9 Hz, H-2'), 2.45 (3H, s, 1-CH₃), 2.26 (3H, s, 9-CH₃), 1.95 (3H, s, H₃-4'), 1.82 (3H, d, J = 6.9 Hz, H-3'); ^{13}C NMR (125 MHz, methanol- d_4) δ_{C} : 163.6 (C, C-11), 158.9 (C, C-3), 155.3 (C, C-4a), 150.7 (C, C-

8), 143.3 (C, C-9a), 143.1 (C, C-1), 141.0 (C, C-5a), 136.1 (C, C-6), 131.1 (C, C-1'), 128.7 (CH, C-2'), 121.5 (C, C-2), 117.9 (C, C-9), 117.6 (C, C-7), 115.6 (C, C-11a), 111.8 (C, C-4), 19.0 (CH₃, 1-CH₃), 17.7 (CH₃, C-4'), 14.2 (CH₃, C-3'). HR-ESIMS *m/z* 429.0067 [M + H]⁺ (calcd for C₁₉H₁₆Cl₃O₅, 429.0063).

Aspergillusidone B (**5**): colorless solid; ¹H NMR (500 MHz, methanol-*d*₄): δ_H 6.89 (1H, s, H-2), 5.36 (1H, qq, *J* = 5.3, 1.9 Hz, H-2'), 3.95 (3H, s, 3-OCH₃), 2.49 (3H, s, 1-CH₃), 2.26 (3H, s, 9-CH₃), 1.94 (3H, s, H-4'), 1.80 (3H, d, *J* = 6.8 Hz, H-3'); ¹³C NMR (125 MHz, Methanol-*d*₄) δ_C: 163.9 (C, C-11), 160.4 (C, C-4a), 160.3 (C, C-3), 150.6 (C, C-8), 145.0 (C, C-1), 143.2 (C, C-9a), 143.2 (C, C-5a), 136.2 (C, C-6), 131.2 (C, C-1'), 128.6 (C, C-2'), 117.9 (C, C-9), 117.6 (C, C-7), 115.4 (C, C-11a), 112.5 (C, C-4), 112.2 (C, C-2), 57.3 (CH₃, 3-OCH₃), 21.7 (CH₃, 1-CH₃), 17.8 (CH₃, C-4'), 14.2 (CH₃, C-3'), 10.2 (CH₃, 9-CH₃). HR-ESIMS *m/z* 409.0620 [M + H]⁺ (calcd for C₂₀H₁₉Cl₂O₅, 409.0610).

Aspergillusidone C (**6**): colorless needles; ¹H NMR (700 MHz, methanol-*d*₄): δ_H 6.53 (1H, s, H-4), 5.37 (1H, q, *J* = 6.8 Hz, H-2'), 2.46 (3H, s, 1-CH₃), 2.22 (3H, s, 9-CH₃), 1.95 (3H, s, H₃-4'), 1.90 (3H, d, *J* = 6.8 Hz, H₃-3'); ¹³C NMR (175 MHz, methanol-*d*₄) δ_C: 164.3 (C, C-11), 162.8 (C, C-3), 159.1 (C, C-4a), 150.3 (C, C-8), 143.4 (C, C-9a), 143.1 (C, C-5a), 142.7 (C, C-1), 135.8 (C, C-6), 130.8 (C, C-1'), 127.9 (CH, C-2'), 121.1 (C, C-2), 117.8 (C, C-9), 117.2 (C, C-11a), 114.8 (C, C-7), 106.4 (CH, C-4), 18.6 (CH₃, 1-CH₃), 17.4 (CH₃, C-4'), 13.7 (CH₃, C-3'), 10.1 (CH₃, 9-CH₃). HR-ESIMS *m/z* 395.0460 [M + H]⁺ (calcd for C₁₉H₁₇Cl₂O₅, 395.0453).

Guisinol (**7**): yellow oil; ¹H NMR (500 MHz, methanol-*d*₄): δ_H 6.75 (1H, d, *J* = 1.8 Hz, H-4'), 6.46 (1H, d, *J* = 1.8 Hz, H-6'), 5.83 (1H, q, *J* = 6.9 Hz, H-2''), 5.28 (1H, q, *J* = 6.7 Hz, H-2''), 2.15 (3H, s, 3-CH₃), 1.97 (3H, s, 2'-CH₃), 1.96 (3H, s, H₃-4''), 1.95 (3H, s, H₃-4''), 1.77 (3H, d, *J* = 6.9 Hz, H₃-3''), 1.72 (3H, d, *J* = 6.7 Hz, H₃-3''); ¹³C NMR (125 MHz, methanol-*d*₄) δ_C: 170.8 (C, C=O), 160.8 (C, C-4), 157.5 (C, C-2), 157.3 (C, C-1'), 151.2 (C, C-3'), 145.2 (C, C-1''), 144.1 (C, C-1''), 136.9 (C, C-6), 135.9 (C, C-5'), 123.8 (C, C-2''), 122.9 (C, C-2''), 116.7 (C, C-2'), 113.8 (C, C-3), 112.9 (C, C-5), 110.7 (C, C-6'), 110.6 (CH, C-4'), 106.7 (C, C-1), 17.5 (CH₃, C-4'') 15.5 (CH₃, C-4'''), 14.3 (CH₃, C-3'''), 13.8 (CH₃, C-3''), 9.5 (CH₃ 2'-CH₃), 9.0 (CH₃, 3-CH₃). HR-ESIMS *m/z* 417.1469 [M + H]⁺ (calcd for C₂₃H₂₆ClO₅, 417.1469).

1-(2,6-dihydroxy-4-methoxy-3,5-dimethylphenyl)-2-methylbutan-1-one (8): brown oil; ^1H NMR (700 MHz, methanol-*d*₄): δ _H 3.75 (1H, m, *J* = 7.1 Hz, H-8), 3.68 (3H, s, 4-OCH₃), 2.09 (3H, s, H₃-13), 2.03 (3H, s, H₃-12), 1.76 (1H, m, H-9a), 1.40 (1H, m, H-9b), 1.14 (3H, d, *J* = 6.8 Hz, H₃-11), 0.87 (3H, t, *J* = 7.6 Hz, H₃-10); ^{13}C NMR (175 MHz, methanol-*d*₄) δ _C: 212.2 (C, C-7), 162.0 (C, C-5), 162.0 (C, C-3), 160.0 (C, C-1), 111.1 (C, C-4), 109.0 (C, C-2), 108.5 (C, C-6), 62.8 (CH₃, 4-OMe), 46.5 (CH, C-8), 28.6 (CH₂, C-9), 17.6 (CH₃, C-11), 12.3 (CH₃, C-10), 9.3 (CH₃, C-13), 8.2 (CH₃, C-12).




Figure S21. Anti-MRSA activity of compounds **1–8** by agar diffusion method. (CHL: Chloramphenicol; SM: Streptomycin; AMP: Ampicillin)



Figure S22. Anti-*M. variabilis* activity of compounds **1–8** by agar diffusion method.




Figure S23. Anti-*M. jannaschii* activity of compounds 1–8 by agar diffusion method.



Figure S24. Anti-*V. Pelagius* activity of compound 4 by agar diffusion method.




Figure S25. Anti-MRSA activity of compounds 1, 2, 4, 6, 7 and ampicillin.




Figure S26. Anti-*M. variabilis* activity of compounds **1, 2, 4, 6~8** and positive control




Figure S27. Anti-*M. jannaschii* activity of compounds **1, 2, 4, 6, 8** and positive control




Figure S28. Anti-*V. Pelagius* activity of compounds **4** and nalidixic acid.

The ITS sequence of *Aspergillus unguis* GXIMD 02505

>ITS1

```
TTTGAGGAGTCGGCTGCTGGGCCACCTCCCACCCTGATACTAAACACTGTT
GCTTCGGCGGGGAGCCCTCCGGGGCAAGCCGCCGGGACCACTGAACCTC
ATGCCTGAGAGTGTGAGTCTGAGTCTGAATTATAAATCAGTCAAAACTTCAAC
AATGGATCTTGGTCCGGCATCGATGAAGAACGCAGCGAATGCGATAAGTAA
TGTGAATTGCAGAATTCACTGAATCATCGAGTCTTGAACGCACATTGCCCTT
GGCATTCCGGGGGCATGCCTGTCGAGCGTCATTGCTGCCCTCAAGCCGGCT
TGTGTGTTGGTCGTCGCCCCCCCAGGGGACGGGCCGAAAGGCAGCGCGC
ACCGTGTCCGGCCTCGAGCGTATGGGGCTTGTCAACCGCTCGATTAGGGCGG
CCGGCGCCAGCCGGCATCAATCTATTTACCAAGGTTGACCTCGGATCAGGT
GGGATACCCGCTGAACCTAACGATATCAATAAGCGGAGGA
```

>ITS4

```
ATACTACTGACTACTGATCGAGGTACCTGGTAATAGATTGATGACGCCGGCTGGC
GCCCGGCCGCCCTAATCGAGCGGGTGACAAAGCCCCATACGCTCGAGGACCGG
ACACGGTGCCCGCTGCCTTCGGGCCGCCCCGGGGACGACGACCCA
ACACACAAGCCGGCTGAAGGGCAGCAATGACGCTCGGACAGGCATGCC
GGAATGCCAGGGGGCGCAATGTGCGTTCAAAGACTCGATGATTCACTGAATTCTG
CAATTACACATTACTTATCGCAGTTCGCTGCGTTCTCATCGATGCCGAACCAAGA
GATCCATTGTTGAAAGTTGACTGATTATAATTCAAGACTCAGACTGCATCACTCT
CAGGCATGAAGTTCAAGGGTGGGAGGTTGGGCCGGAGGCAG
CCGAAGCAACAGTGTAGTATTCAAGGGTGGGAGGTTGGGCCGGAGGCAG
```

CCCGCACTCGGTAAATGATCCTTCCGCAGGTTACCTACGGAAG